RGFP966

RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor. RGFP966 treatment on two CTCL cell lines for 24 hours prior to Western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression.

Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.